Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Ohad Benjamini, Lior Rokach, Gilad Itchaki, Andrei Braester, Lev Shvidel, Neta Goldschmidt, Shirley Shapira, Najib Dally, Abraham Avigdor, Galia Rahav, Yaniv Lustig, Shirley Shapiro Ben David, Riva Fineman, Alona Paz, Osnat Bairey, Aaron Polliack, Ilana Levy, Tamar Tadmor
Format:	Artigo
Język:	Inglês
Wydane:	Ferrata Storti Foundation 2021-07-01
Seria:	Haematologica
Dostęp online:	https://haematologica.org/article/view/10351
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!